PMC4821145_01
Response to treatment. Primary tumor in the left lower lobe. Complete metabolic response to crizotinib as indicated by 18F-FDG-PET/CT scans before (a) and after 4.5 months of treatment (b). Partial response according to RECIST 1.1 criteria: tumor shrinkage from 33 to 13 mm before (c) and after 4.5 months of crizotinib (d).
cro-0009-0158-g01.jpg
PMC4821145_01_cro-0009-0158-g01.jpg
F1
In a 18F-FDG-PET/CT scan, the primary lesion was present with a SUVmax of 19.7 (fig. 1).
Histological and molecular findings. a Solid type of pulmonary adenocarcinoma (H&E). b
ROS1 translocation detected by FISH. Green probes flank the 3' end of the ROS1 gene; normal cells display orange-green fusion signals. Gene rearrangements are indicated by either isolated green signals or break-apart signals of orange and green signals or a combination of both patterns in >=15% of tumor cells (probe provided by ZytoVision, Bremerhaven, Germany).
cro-0009-0158-g02.jpg
PMC4821145_01_cro-0009-0158-g02.jpg
F2
However, fluorescence in situ hybridization (FISH) analysis for ROS1 rearrangement showed aberrant probe signals in 81 of 100 evaluated tumor cell nuclei (fig. 2).